The debate over the heartburn medication Zantac and its alleged links to cancer heated up in Cook County this past week, with one case being settled, another reaching a confidential resolution, and an additional complaint getting dropped. Two Illinois residents who claimed that their use of Zantac resulted in cancer quietly settled their disputes with pharmaceutical giant GSK, while another plaintiff opted to withdraw her case earlier in June. Notably, GSK, who sold Zantac for several periods, has asserted throughout the litigation that there's no evidence to suggest their product raises cancer risks.
According to a statement obtained by the Chicago Sun-Times, GSK highlighted that "the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer." Despite this, plaintiff allegations persist, centering on the claim that ranitidine, the primary compound in Zantac, can degrade into a carcinogenic substance known as NDMA (nitrosodimethylamine). However, the FDA's position has evolved; it first requested the removal of Zantac from the market in 2020, then later concluded there was no danger to users, leaving Zantac 360, which does not contain ranitidine, on the shelves.
The legal skirmish received its initial spotlight with the trial of Angela Valadez, an 89-year-old woman who sued GSK and Boehringer Ingelheim. Her case, which was the first jury trial to assess Zantac's cancer risks, ended in a verdict favoring the defendants. NBC Chicago reported, that after three weeks of testimonies and arguments, the jury rejected the link between Zantac and the plaintiff's colon cancer. Valadez, who sought $640 million in damages, alleged she developed the cancer after taking Zantac for 18 years.
The lawsuits are part of a broader wave of legal actions where plaintiffs nationwide allege they developed cancer from Zantac usage. Both GSK and Boehringer Ingelheim maintain their stance on the science of their product. Speaking to the Chicago Sun-Times, GSK expressed a dedication to "vigorously defend itself and manage this litigation in the best interests of the company and shareholders." Recovering profits and reputations might be a long path for the companies, with the court of public opinion often proving less predictable than the science they cite as a defense.
